Friday

8-9  Priorities and challenges in population screening for T1D
9-12:30  Reports from current general population screening programs
12:30-1:00  lunch
1-2:30  Standardization of immune markers for screening
2:45-4:40  Guidelines for monitoring and education in pre-T1D
Thank you

This program was developed independently by the Barbara Davis Center for Diabetes and supported in part by educational grants from Sanofi US and the Children’s Diabetes Foundation.
Practical issues

• If you are participating by Zoom, **type questions in the Q&A window**
• The symposium recording will be posted on the website within 10 days; use this QR:

![QR code image]

• Please try to keep in-room audience sound to a minimum
Practical issues

• Please direct logistic questions to:
  Christy Vasey
  Christy.Vasey@cuanschutz.edu  303 803-8887

• Please direct audio-visual or IT questions to:
  Josh Hartz
  Joshua.Hartz@cuanschutz.edu  303 591-0345

Thank you!
Priorities and Challenges in Population Screening for T1D

Questions to Panelists from the NIH, JDRF, and Helmsley Charitable Trust

Beena Akolkar, PhD, Program Director
Sanjoy Dutta, PhD, Chief Scientific Officer
Esther Latres, PhD, Vice President, Research
Gina Agiostratidou, PhD, Program Director
Anne Koralova, PhD, Program Officer
Who should be screened for islet autoantibodies?

Currently recommended by the ADA:
- People with a family history of T1D
- People w/o family history participating in research studies (e.g., ASK)
- Children with a high T1D GRS participating in research studies

Clinically acceptable
- People with an autoimmune condition and their relatives
- People with dysglycemia or symptoms suggesting undiagnosed diabetes

Likely accepted in the near future
- All children and adolescents
- Adults (age limit?)
1. Are we ready to recommend routine screening of general population children for islet autoantibodies? If not quite yet, what are the barriers?

2. Are we ready to recommend routine screening of general population adults for islet autoantibodies?

3. What are your organization’s priorities in the area of T1D screening, in the next 1-3 years?